Therakind, as a specialty pharmaceutical company, is focused on developing niche medicines in difficult to treat patient groups including children, the elderly and those suffering from chronic illness. Therakind looks for areas of unmet medical need in these patient groups and then creates, develops and improves medicines to help meet these needs.

Therakind has already successfully brought three speciality medicines to market and has a patented intranasal delivery device ready for development partnering.

• Jylamvo^®– methotrexate oral solution 2 mg/ml for children ≥ 3 years old and adults approved for use across the EU and the US
• Buccolam^®– midazolam oromucosal solution for children from 3 months to < 18 years. This product was sold in 2010 to Viropharma Inc (subsequently acquired by Neuraxpharm UK Ltd) and is being marketed across Europe.
• Ayendi^®– intranasal diamorphine for children aged 2-15 years old
• DriDose^®.   is a Dry Powder Intranasal Device which can be utilised for nasal delivery of vaccines, peptides, proteins and small molecules (avoids IV route and first pass metabolism of oral route)

 

An extensive pipeline of products is under development.

Read more on our Spotlight Section.